Simulations Plus Inc (SLP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Simulations Plus Inc (SLP) has a cash flow conversion efficiency ratio of 0.033x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.23 Million) by net assets ($127.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Simulations Plus Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Simulations Plus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SLP total liabilities for a breakdown of total debt and financial obligations.
Simulations Plus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Simulations Plus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ainsworth Game Technology Ltd
AU:AGI
|
-0.022x |
|
Ssangyong Information & Communications Corp
KQ:010280
|
0.172x |
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
N/A |
|
Service Properties Trust
NASDAQ:SVC
|
0.151x |
|
Dagang Nexchange Bhd
KLSE:4456
|
0.054x |
|
Veedol Corporation Limited
NSE:VEEDOL
|
N/A |
|
CHINA KEPEI ED. DL-00001
F:9CK
|
N/A |
|
BenQ Materials Corp
TW:8215
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Simulations Plus Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Simulations Plus Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Simulations Plus Inc (SLP) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $124.80 Million | $18.13 Million | 0.145x | +98.92% |
| 2024-08-31 | $182.43 Million | $13.32 Million | 0.073x | -43.20% |
| 2023-08-31 | $170.03 Million | $21.86 Million | 0.129x | +28.00% |
| 2022-08-31 | $178.25 Million | $17.90 Million | 0.100x | -13.30% |
| 2021-08-31 | $165.78 Million | $19.20 Million | 0.116x | +65.64% |
| 2020-08-31 | $156.04 Million | $10.91 Million | 0.070x | -77.36% |
| 2019-08-31 | $37.68 Million | $11.64 Million | 0.309x | +6.16% |
| 2018-08-31 | $31.92 Million | $9.29 Million | 0.291x | +9.15% |
| 2017-08-31 | $25.80 Million | $6.88 Million | 0.267x | +11.89% |
| 2016-08-31 | $22.73 Million | $5.42 Million | 0.238x | -34.79% |
| 2015-08-31 | $19.53 Million | $7.13 Million | 0.365x | +6.26% |
| 2014-08-31 | $15.44 Million | $5.31 Million | 0.344x | +91.08% |
| 2013-08-31 | $14.24 Million | $2.56 Million | 0.180x | -28.00% |
| 2012-08-31 | $15.14 Million | $3.78 Million | 0.250x | +0.29% |
| 2011-08-31 | $14.04 Million | $3.50 Million | 0.249x | +11.86% |
| 2010-08-31 | $13.05 Million | $2.91 Million | 0.223x | -5.50% |
| 2009-08-31 | $10.57 Million | $2.49 Million | 0.236x | -5.64% |
| 2008-08-31 | $9.92 Million | $2.48 Million | 0.250x | -35.39% |
| 2007-08-31 | $7.66 Million | $2.96 Million | 0.387x | +90.98% |
| 2006-08-31 | $5.67 Million | $1.15 Million | 0.202x | -31.56% |
| 2005-08-31 | $4.86 Million | $1.44 Million | 0.296x | +128.72% |
| 2004-08-31 | $4.45 Million | $575.05K | 0.129x | -21.73% |
| 2003-08-31 | $3.28 Million | $541.85K | 0.165x | +14.24% |
| 2002-08-31 | $767.88K | $111.07K | 0.145x | -85.99% |
| 2001-08-31 | $282.97K | $292.10K | 1.032x | +239.14% |
| 2000-08-31 | $486.07K | $147.95K | 0.304x | +152.85% |
| 1999-08-31 | $740.66K | $89.16K | 0.120x | +111.96% |
| 1998-08-31 | $1.28 Million | $-1.29 Million | -1.007x | -141.11% |
| 1997-08-31 | $3.35 Million | $-1.40 Million | -0.418x | -183.51% |
| 1996-08-31 | $200.00K | $100.00K | 0.500x | -- |
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans… Read more